Measuring mtDNA damage together with LRRK2 phosphorylation is an innovative biomarker approach to determine LRRK2 kinase activity and may be helpful in considering the drug efficacy of compounds targeting hyperactive kinase activity in G2019S LRRK2 PD patients in the context of a clinical trial. The gene discussed is LRRK2; the disease is Parkinson disease.